Archives

Immunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

B IMT-009 was generally well tolerated as monotherapy and in combination with fruquintinib, demonstrating early signs of anti-tumor activity in heavily pretreated patients Translational findings… Login to continue reading Login…

Read MoreImmunitas Presents Phase 1/2a Data Highlighting Anti-Tumor Activity of Novel Immunotherapy IMT-009 at AACR 2026 Annual Meeting

Dr. Ronald Bernardini Opens Doors for Future Health Professionals With Nationwide Undergraduate Scholarship Initiative

Array Dr. Ronald Bernardini Opens Doors for Future Health Professionals With Nationwide Undergraduate Scholarship Initiative A $1,000 Essay Competition Invites Aspiring Healthcare Students Across America… Login to continue reading Login…

Read MoreDr. Ronald Bernardini Opens Doors for Future Health Professionals With Nationwide Undergraduate Scholarship Initiative